Department of Chemical Engineering, Faculty of Engineering and Science, Universidad de La Frontera, Temuco, Chile.
Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Santiago de Chile, Chile.
Med Oncol. 2023 Apr 15;40(5):150. doi: 10.1007/s12032-023-02014-9.
L-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the L-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases.
L-天冬酰胺酶是一种抗白血病药物，长期以来被批准用于临床治疗儿童急性淋巴细胞白血病，这是全世界此类人群中最常见的癌症。然而，由于接受治疗的患者会出现各种不良反应，以及在血浆中迅速消除、需要多次给药和高过敏反应率等原因，其疗效及其作为药物的使用一直存在争议。出于这个原因，寻找新的、免疫原性更低的变体一直是研究的主题。本综述从结构、药理学和临床的角度，从其与其他药物联合用于不同治疗阶段的化疗方案的角度，介绍了 L-天冬酰胺酶酶的主要方面。
